European Urology

Viewing slides 1-6 of 8

• S0302-2838(10)00863-8.title drag remove slide sort drag into slide Title Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic ... Zoom
• S0302-2838(10)00863-8.introduction drag remove slide sort drag into slide Introduction In metastatic renal cell carcinoma (mRCC), the transition to the so-called targeted therapy era has made available an unprecedented variety of effective new agents such as sunitinib, sorafenib, ... In metastatic renal cell carcinoma (mRCC), the transition to the so-called targeted therapy era has ... Zoom
• 17916 drag remove slide sort drag into slide Progression-free survival (PFS) from the start of sorafenib. Zoom read this article »
• 17918 drag remove slide sort drag into slide Overall survival (OS) from the start of sorafenib. Zoom read this article »
• 17920 drag remove slide sort drag into slide Best percentage change from baseline in sum of longest diameters based on ... Zoom read this article »
• S0302-2838(10)00863-8.materials_and_methods drag remove slide sort drag into slide Materials and methods Patients complying with the following criteria were included in this analysis:
  
  (1) histology diagnosis of mRCC;
  
  (2) baseline radiographic assessment and at least one radiographic evaluation ... Patients complying with the following criteria were included in this analysis: (1) histology ... Zoom

Viewing slides 1-6 of 8